Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion
TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the successful completion of its comprehensive GLP safety study for its engineered neural...
TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the successful completion of its comprehensive GLP safety study for its engineered neural...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.